(Corrects third to last paragraph to say "the erosion from LOEs (loss of exclusivity)", not "from LOEs (levels of evidence)") ...

智通财经获悉，默克公司 (Merck KGaA)表示，收购美国癌症和罕见疾病制药公司SpringWorks Therapeutics ...

Stamford, Connecticut-based SpringWorks' Gomekli (mirdametinib) has become the first medicine approved for both adults and ...

Germany-based Merck KGaA (OTC:MKGAF) (OTC:MKKGY) reacted to press reports and confirmed advanced discussions with SpringWorks ...

Germany’s Merck KGaA is in advanced talks for a potential acquisition of SpringWorks Therapeutics, a U.S. biopharmaceutical ...

Merck KGaA, the German healthcare and technology group, is in advanced talks to acquire U.S. cancer and rare diseases ...

Merck KGaA said it’s in advanced talks to purchase SpringWorks Therapeutics Inc., sending shares of the US cancer and rare ...

近日（2月10日），据路透社报道，德国制药巨头默克（Merck KGaA）正在就收购美国生物技术公司SpringWorks Therapeutics进行谈判，交易金额可能高达34亿至40亿美元。 随后，Merck ...

As SpringWorks Therapeutics nears a key regulatory decision in the U.S., the Connecticut-based cancer and rare disease ...

Merck said in a brief statement that discussions are "advanced" but noted that "critical conditions have yet to be met" ...

Wedbush raised the firm’s price target on SpringWorks Therapeutics (SWTX) to $81 from $77 and keeps an Outperform rating on the shares ...

近日，美国生物制药公司SpringWorks Therapeutics (SWTX.US)的股价在市场上喜迎一波34%的爆发，市值迅速突破40亿美元。这一异动的背后，是德国默克公司 (Merck KGaA) 展示出的收购意向。随着双方谈判的进行，这场交易可能在未来几周内就会敲定，给投资者带来无限遐想和期待。 在投资者对科技公司和制药业的热情不断高涨的市场环境中，SpringWorks ...